

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025 Commission File Number 001-41666 CASI PHARMACEUTICALS, INC. (Translation of registrant's name into English) 1701-1702, China Central Office Tower 1 No. 81 Jianguo Road, Chaoyang District Beijing, 100025 People's Republic of China (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F x Form 40-F " CASI Pharmaceuticals Receives Asset Freezing Order from Court of P.R. China On January 21, 2025, CASI Pharmaceuticals, Inc., a Cayman Islands incorporated company (the "CASI" or the "Company") announced that the Company received on January 17, 2025 an asset freezing order (the "Asset Freezing Order") from a court of P.R.C. with respect to the Company's previously announced dispute with Juventas Cell Therapy Ltd. (the "Juventas") and the related arbitration proceedings initiated at the Hong Kong International Arbitration Centre in connection to Juventas's purported termination of the parties' agreements with respect to the commercialization of CNCT19 (the "Arbitration Proceeding"). In the Asset Freezing Order, the Fourth Intermediate People's Court of Beijing Municipality, granted Juventas' application to freeze the Company's assets while the Arbitration Proceeding is ongoing and decided to freeze up to RMB 250 million of the Company's assets. To enforce the Asset Freezing Order, the court has decided to freeze the transfer of certain equity interest the Company owns in its subsidiaries in the P.R.C. No other asset has been affected. The Company does not expect that such action will have material adverse effects on its day-to-day operations. The Company will continue to vigorously assert and enforce its rights against Juventas through all available legal means. The Company cannot predict right now the final outcome of the Arbitration Proceeding or how the parties' dispute would ultimately be resolved. Forward-Looking Statements This 6-K contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. All information provided herein is as of the date of this 6-K, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. We caution readers not to place undue reliance on any forward-looking statements contained herein. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CASI Pharmaceuticals, Inc. By: /s/ Wei-Wu He Name: Wei-Wu He Title: Chairman & CEO Date: January 21, 2025